{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Toribio M"],"funding":["NICHD NIH HHS","NIAID NIH HHS","NHLBI NIH HHS"],"pagination":["64-73"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9942173"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["<h4>Purpose</h4>Through a survey-based approach, we sought to investigate regional differences in gender-affirming hormone therapy (GAHT) prescribing practices, as well as HIV screening and prevention practices among clinicians providing care to transgender individuals.<h4>Methods</h4>Our survey was disseminated between December 2019 and January 2021 to clinicians who prescribe GAHT within New England (United States). Between-group differences in GAHT prescribing and HIV screening/prevention practices were evaluated by practice setting and subspecialty.<h4>Results</h4>Of the 20 survey respondents, 55% practiced in health care settings affiliated with an academic institution, 45% practiced in a community-based health care setting, and 30% were Endocrinologists. Clinicians in community-based"],"journal":["Transgender health"],"pubmed_title":["Hormone Prescription and HIV Screening/Preventive Practices Among Clinicians Providing Care for Transgender Individuals."],"pmcid":["PMC9942173"],"funding_grant_id":["P2C HD050924","K23 HL147799","K24 AI157882"],"pubmed_authors":["Fulda ES","Toribio M","Donelan K","Cetlin M","Poteat T","Chu SM","Gomez Tejeda Zanudo J","Zanni MV"],"additional_accession":[]},"is_claimable":false,"name":"Hormone Prescription and HIV Screening/Preventive Practices Among Clinicians Providing Care for Transgender Individuals.","description":"<h4>Purpose</h4>Through a survey-based approach, we sought to investigate regional differences in gender-affirming hormone therapy (GAHT) prescribing practices, as well as HIV screening and prevention practices among clinicians providing care to transgender individuals.<h4>Methods</h4>Our survey was disseminated between December 2019 and January 2021 to clinicians who prescribe GAHT within New England (United States). Between-group differences in GAHT prescribing and HIV screening/prevention practices were evaluated by practice setting and subspecialty.<h4>Results</h4>Of the 20 survey respondents, 55% practiced in health care settings affiliated with an academic institution, 45% practiced in a community-based health care setting, and 30% were Endocrinologists. Clinicians in community-based","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-05T00:01:54.917Z","creation":"2025-04-05T00:01:54.917Z"},"accession":"S-EPMC9942173","cross_references":{"pubmed":["36824383"],"doi":["10.1089/trgh.2021.0118"]}}